MedicalResearch.com Interview with:
Dr. Jay Edelberg MD, PhD
VP Head of Cardiovascular Development and
Head Global Cardiovascular Medical Affairs
MedicalResearch.com: What should readers take away from the data that Sanofi and Regeneron is presenting at ESC Congress 2017?
Response: This year at European Society of Cardiology (ESC,) we are pleased to present analyses that further demonstrate additional efficacy and tolerability of Praluent (alirocumab).
While statins remain the first-line treatment, Praluent has shown a consistent benefit as an additional therapy to high-intensity statins in patients with clinical atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH), allowing many patients to achieve low-density lipoprotein (LDL) cholesterol levels previously considered unattainable in this patient population.
Our data further emphasize the need for additional cholesterol-lowering options in these high cardiovascular (CV) risk patient populations, including individuals living with diabetes.
MedicalResearch.com: What recommendations or thoughts do you have about future research?
Response: We have a shared goal with patients, physicians and insurers to reduce the burden of elevated LDL cholesterol and cardiovascular disease, and believe cardiovascular outcomes trials (CVOTs) will ultimately determine the long-term value of the PCSK9 inhibitor class.
We remain focused on ODYSSEY OUTCOMES, which evaluates the effect of Praluent on cardiovascular events in more than 18,000 patients for duration of follow-up up to 5 years, and is expected to be completed in late 2017, with topline results in early 2018.
We hope additional CVOT data for the PCSK9 inhibitor class will help reassure payers on the value of the class and improve access concerns, as many patients already face significant challenges getting prescribed PCSK9 inhibitor treatment.
MedicalResearch.com: Is there anything else you would like to add?
Response: For high risk patients, including those with acute coronary syndrome (ACS) or HeFH, cholesterol management and goal achievement is still not optimal.
It is unfortunate that many eligible patients are still unable to obtain access to treatment. For these high-risk patients, Praluent provides an important treatment option to achieve improved cholesterol management.
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
Dr. Edelberg was discussing the 2017 ESC Congress abstract:
Predictive factors for alirocumab dose increase in patients with hypercholesterolemia and high cardiovascular risk: from the ODYSSEY COMBO I and II trials
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.